What’s Hot Besides Deciphera Pharmaceuticals, Inc. (DCPH) Stock?

If you’re on the hunt for stocks to watch today, Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) is a stock to give close attention to. The company shares are trading 3.54% or 1.34 points up from last closing price of $37.87, reaching $39.21 at last check. The DCPH share price has risen in 4 of the last 5 days and is up 54.13% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -464,009 shares, and in total 430091 shares valued at $16.864 million were seen changing hands compared with 894100 shares valued at $33.86 million recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in DCPH stock for the next couple of days.

Deciphera Pharmaceuticals, Inc. (DCPH) shares have notched a 3-month gain of about 54.13%, but has still advanced 80.42% year to date. By comparison, the stock added 6.77% over the past 12 months, while it jumped 75.81% over the 1 month. The company’s market cap is around $1.9B, with its short interest ratio standing at 4.66%.

In the current trading session for DCPH, the stock witnessed two major price actions, it rose to a high of $39.38 and was down as much as $37.44 at one point. The high recorded is very low when compared to their 52-week high which is $18.55. The 52-week high is now at -8.77 distance from current price. Their recent low of $42.99 represents a 111.43% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for DCPH is $53.09, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of Deciphera Pharmaceuticals, Inc. earned $-3.31 per share in the trailing 12 months and has a P/E ratio of -11.85. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 69.38 and lower compared to the sector’s average of 32.67. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. DCPH also has P/S multiple of 78.89. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 49.44x.

The company recorded an interesting insider sale transaction by the Major Shareholder on Aug 16, 2019. A Securities and Exchanges Commission filings show that New Leaf Venture Management Ii sold a total of 350,000 DCPH shares that day for a sum of around $12,747,000. Deciphera Pharmaceuticals, Inc. (DCPH) insiders have acquired no shares in the stock within the past three months. In total, individual insiders traded 559,134 shares in the business, which makes up 66.206% of 844,533 shares that were traded over a year. In the past 12 months, insiders have purchased 72,000 shares while the seller parted with 772,533 shares.

DCPH‘s last price was up 58.03% as compared to the average trading price of 50 days recorded at $24.81 while enlarging the period to 200 trading days, the average closing price was $25.68. At present, there are 50.3 million in the total number of common shares owned by the public and among those 32.28 million shares have been available to trade. The percentage of shares being held by the company management was 0.2% while institutions stake was 48.6%. The company has generated negative returns on equity over the last 12 months (-47.7%). It managed to keep its gross profit margin at 0% over the past 12 months.

When assessing the full upside of the DCPH stock, there is another set of technicals that should be looked into and considered. Its 29.03% gain from moving average of $30.39 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 0 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Deciphera Pharmaceuticals, Inc. — 8 analysts rate the stock as a buy with another 0 rating it strong buy. There are 1 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $50.3333 on shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), which corresponds to 27.81% upside potential than its current market price of $39.21 and implies potential despite the recent advance in the price. However, their current target price has climbed from $43 a month ago and is up handily from the consensus target of $44 a quarter ago.

In the last five years, the EPS of the company has been roughly 0%. Though the percentage looks disappointing, extra tailwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will increase annually by 23.18%. The revenue of the company has retreated at an average annualized rate of about 0 over the last five years. The company recently recorded a drop of 0%, but this figure is rather unattractive.

Let’s briefly check the hedge fund interest towards DCPH stock. SV Health Investors LLC trimmed position in the company after it dumped -25.8% or 1,237,651 shares of its common stock. The hedge fund now owns 918,337 shares worth $36,007,994, SEC documents show. Citadel Advisors LLC cut assets in the stock as 364895.2 shares have been sold, reducing its stake by -20.8% to 288,997 shares which are currently valued at $11,331,572. In addition, Cubist Systematic Strategies LLC recently reported that it now owns 13,563 shares making a total of $531,805 based on the recent price. This refelects a change of 55.7% in their ownership.